SEC Comment Letter for ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Oct 9, 2019
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: Oct. 9, 2019 · CIK: 0001368514 · Accession: 0000000000-19-014431
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234107
Letter
October 9, 2019 Adam S. Grossman Chief Executive Officer ADMA Biologics, Inc. 465 State Route 17 Ramsey, NJ 07446 Re:ADMA Biologics, Inc. Registration Statement on Form S-3 Filed October 4, 2019 File No. 333-234107 Dear Mr. Grossman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David C. Schwartz, Esq.
Show Raw Text
October 9, 2019
Adam S. Grossman
Chief Executive Officer
ADMA Biologics, Inc.
465 State Route 17
Ramsey, NJ 07446
Re:ADMA Biologics, Inc.
Registration Statement on Form S-3
Filed October 4, 2019
File No. 333-234107
Dear Mr. Grossman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David C. Schwartz, Esq.